We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (“CNS”) disorders, lysosomal storage disorders (“LSDs”), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 1 · ActiveModality: oral small molecule (allosteric GCase modulator)
Aliases GT-02287
Target GCase (glucocerebrosidase)
Partnerships Minoryx Therapeutics: exclusive worldwide license to Magellan platform/STAR compounds (Dec 2017); royalty-bearing; term 10 years post first commercialization
Indications
Parkinson's disease with GBA1 mutation(Phase 1)
Parkinson's disease without GBA1 mutation(Phase 1)
Catalysts
— Q3 2026
— October 2026
Status note Lead candidate; Phase 1a in healthy volunteers complete; Phase 1b in people with Parkinson's ongoing (Part 1 complete; Part 2 extension ongoing). FDA IND authorized June 2026 for Phase 2a.
GT-04686
Preclinical · ActiveModality: oral small molecule (allosteric GCase modulator)
Target GCase (glucocerebrosidase)
Partnerships Minoryx Therapeutics: same Magellan platform license
Indications
not disclosed(Preclinical)
Status note Structurally distinct series of allosteric GCase modulators; ready to advance into IND-enabling studies. Indication not stated.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.